Rituximab Infusion Timing, Cumulative Dose, and Hospitalization for COVID-19 in Persons With Multiple Sclerosis in Sweden

This case-control study examines the risk of severe COVID-19 infection in individuals with multiple sclerosis who were receiving rituximab.

Detalles Bibliográficos
Autores principales: McKay, Kyla A., Piehl, Fredrik, Englund, Simon, He, Anna, Langer-Gould, Annette, Hillert, Jan, Frisell, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2021
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637249/
https://www.ncbi.nlm.nih.gov/pubmed/34851401
http://dx.doi.org/10.1001/jamanetworkopen.2021.36697

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8637249/
https://www.ncbi.nlm.nih.gov/pubmed/34851401
http://dx.doi.org/10.1001/jamanetworkopen.2021.36697

Ejemplares similares